Thermo Fisher to acquire Clario Holdings, the clinical trial data firm, for $8.9 billion in cash is in news and the same has been announced by the companies on October 29. Clario is at present held by a shareholder group that is led by Novo Holding, Astorg, Nordic Capital, and Cinven.
Besides this, Thermo has also agreed to pay $125 million in January 2027 and almost $400 million in payments based upon the performance of the business in 2026 as well as 2027.
It is well to be noted that Clario happens to integrate clinical trial endpoint data from the devices and sites as well as patients. The company is anticipated to complement the existing clinical research services of Thermo and also drive costs out of the drug development process for its customers, Casey Woodring, the analyst from J.P. Morgan, wrote in a research note.
Clario, apparently, happens to offer services to go ahead and collect data from clinical outcomes, wearables, medical imaging, and other systems. The data gets used across regulatory, pricing, and also reimbursement decisions. Notably, Clario has gone on to support almost 70% of FDA drug approvals throughout the past decade, as per the announcement.
Chris Fikry, the CEO of Clario, said in a statement that he anticipates the scale and relationships of Thermo with pharma as well as biotech leaders to fuel the company’s clinical trial platform expansion.
The fact is that Clario is going to become part of the Laboratory Products and Biopharma Services segment of Thermo post the deal closing. Clario happens to have almost 4,000 employees and is anticipated to generate almost $1.25 billion in terms of revenue for the entire year of 2025.
With Thermo Fisher to acquire Clario Holdings, the former anticipates the deal to be immediately accretive when it comes to its adjusted operating margins and for the transaction to deliver almost $175 million in terms of adjusted operating income by the fifth year.
Thermo also plans to fund acquisition through using proceeds coming from debt financing and, of course, cash on hand. This deal is anticipated to close mid-2026, subject to the numerous customary closing conditions that are put in place and, along with it, all the necessary regulatory approvals.
